Mohs Surgery Is the Treatment of Choice for Recurrent (Previously Treated) Basal Cell Carcinoma

Rowe, Dan; Carroll, Raymond J.; Day, Calvin L.

doi:10.1111/j.1524-4725.1989.tb03249.x

Cited by 439 publications

(324 citation statements)

References 43 publications

(55 reference statements)

Supporting

Mentioning

286

Contrasting

Unclassified

Order By: Relevance

“…8 The reported recurrence rate in current literature is 1-3% in pBCC and 5-7% for rBCC. [8][9][10] Our incidence of 0.26% with pBCC improves on this. Table 3 showed recurrence rates of previous studies that have 5 years follow-up results.…”

Section: Discussionmentioning

confidence: 57%

5 Years review of periocular basal cell carcinoma and proposed follow-up protocol

Brown

Bamford

et al. 2012

Eye

View full text Add to dashboard Cite

In all, 67% were nodular BCC and 45.4% located in the lower eyelid. The main outcome measure was the recurrence rate. None of the patients with primary nodular BCC suffered recurrence. The recurrence rate for primary morphoeaform BCC following complete excision is 3.8%. In total, 8.1% of patients had several lesions simultaneously whereas 7.8% patients had BCC in multiple locations subsequently (metachronous). Three patients who had previously recurrent BCC (rBCC) treated elsewhere or not using this method had orbital/lacrimal drainage system involvement requiring exenteration. Conclusion We recommend that patients with a single, completely excised primary solid or nodular BCC can be discharged after one 6-monthly review, although they should be instructed to monitor for the development of further lesions. The incidence of recurrence for primary morphoeaform BCC is 3.8% and for rBCC is 3.6% over 5 years and these patients should stay under review for this period.

show abstract

Section: Discussionmentioning

confidence: 57%

5 Years review of periocular basal cell carcinoma and proposed follow-up protocol

Brown

Bamford

et al. 2012

Eye

View full text Add to dashboard Cite

show abstract

“…In systematic reviews of the literature dating back to the 1940s, Rowe et al, reported 5-year recurrence rates for MMS of 1% and 5.6% for primary and recurrent BCC, respectively. 42,43 In comparison, recurrence rates for other treatment modalities, including standard excision, C&E, radiation therapy, and cryosurgery ranged from 7.5% to 10.1% and from 9.8% to 40% for primary and recurrent BCC, respectively. The first RCT for MMS comparing MMS with standard excision of primary and recurrent facial BCC was conducted in the Netherlands.…”

Section: Standard Excisionmentioning

confidence: 99%

Guidelines of care for the management of basal cell carcinoma

Baum¹,

Bordeaux²,

Brown³

et al. 2018

Journal of the American Academy of Dermatology

316

219

View full text Add to dashboard Cite

Basal cell carcinoma (BCC) is the most common form of human cancer, with a continually increasing annual incidence in the United States. When diagnosed early, the majority of BCCs are readily treated with office-based therapy, which is highly curative. In these evidence-based guidelines of care, we provide recommendations for the management of patients with BCC, as well as an in-depth review of the best available literature in support of these recommendations. We discuss biopsy techniques for a clinically suspicious lesion and offer recommendations for the histopathologic interpretation of BCC. In the absence of a formal staging system, the best available stratification based on risk for recurrence is reviewed. With regard to treatment, we provide recommendations on treatment modalities along a broad therapeutic spectrum, ranging from topical agents and superficially destructive modalities to surgical techniques and systemic therapy. Finally, we review the available literature and provide recommendations on prevention and the most appropriate follow-up for patients in whom BCC has been diagnosed. ( J Am Acad Dermatol

show abstract

“…Positive margins on dura mater and the mastoid bone required adjuvant radiotherapy. [16,17]. Exceeding the advantages, it is timeconsuming and costs are greatly higher than classic excision [6].…”

Section: Discussionmentioning

confidence: 99%

Invasive basosquamous cell carcinoma of the head treated with wide excision and reconstruction with fascia lata graft and two muscle flaps. Case report

Chelmuș¹,

Dobreanu²,

Tripa³

et al. 2015

Arch Clin Cases

View full text Add to dashboard Cite

Background: Basosquamous carcinoma (BSC) is a variant of basal cell carcinoma subtype that is locally aggressive with high tendency for recurrence and metastasis and a poor prognosis. Up to 95% are located in head and neck area. Treatment for invasive BSC with aggressive growth pattern is wide excision and reconstruction. Complex defects require free tissue transfer to protect underlying structures and to sustain the adjuvant radiotherapy.Case report: A 57 year-old male presented with ulcerated, bleeding tumors in frontal and periauricular area, identified as BSC on biopsy. CT-scan revealed contact to dura mater. Wide excision included frontal bone and dura mater, frontal sinus, lateral orbital wall and exenteration, ear en-bloc with parotid gland. Dura mater was replaced with fascia lata graft, frontal sinus was filled with pedicled temporalis muscle and 20/25 cm soft tissue defect was covered with free Latissimus dorsi muscle anastomosed to superior thyroid artery and internal jugular vein branch, respectively. The muscle was skin grafted 14 days later.Results: Postoperative recovery was complicated: cerebrospinal fluid leak, extradural hematoma, posthemorrhagic anemia, pneumonia, and withdrawal syndrome, remitted under specific treatment. Muscle flap survived entirely with skin graft fully integrated. Positive margins on dura mater and mastoid bone required radiotherapy.Conclusions: Wide excision of head invasive BSC resulted in complex defect reconstructed with fascia lata graft, temporalis muscle and Latissimus dorsi free flap grafted secondarily. Short-term evaluation showed no recurrence and good life-quality; follow-up is needed to evaluate long-term results. Interdisciplinary approach is the key for patient's successful treatment.

show abstract

Mohs Surgery Is the Treatment of Choice for Recurrent (Previously Treated) Basal Cell Carcinoma

Cited by 439 publications

References 43 publications

5 Years review of periocular basal cell carcinoma and proposed follow-up protocol

5 Years review of periocular basal cell carcinoma and proposed follow-up protocol

Guidelines of care for the management of basal cell carcinoma

Invasive basosquamous cell carcinoma of the head treated with wide excision and reconstruction with fascia lata graft and two muscle flaps. Case report

Contact Info

Product

Resources

About